Hematological Malignancy: Clinical Trials

6 trials for Hematological Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 6
Phase 14Completed 4

Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Evomela, Fludarabine, Total Body Irradiation - Hematological Malignancy, Multiple Myeloma
Phase 2CompletedMedical College of Wisconsin432017-12-082026-01-27
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®) - Hematological Malignancy
Phase 1 / Phase 2CompletedCorewell Health West282012-04-012023-06-02
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
AlloStim - Hematological Malignancy, Leukemia
Phase 1 / Phase 2CompletedMirror Biologics, Inc.62010-12-012020-01-22
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Isatuximab SAR650984, Dexamethasone - Hematological Malignancy
Phase 1 / Phase 2CompletedSanofi3512010-05-112024-11-01
Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation
donor lymphocyte infusion - Hematological Malignancy
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris112010-02-012013-01-14
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation
reduced intensity conditionings - Allograft, Allogeneic Cell Transplantaion
Phase 2CompletedInstitut Paoli-Calmettes1482002-11-012014-01-01

Narrower conditions

Hematologic Neoplasms (6)  ·  Multiple Myeloma (2)  ·  Hematologic Diseases (1)  ·  Hodgkin Disease (1)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Broader conditions

Hemic and Lymphatic Diseases (6)  ·  Neoplasms (6)  ·  Neoplasms by Site (6)  ·  Hematologic Diseases (5)  ·  Blood Protein Disorders (2)  ·  Cardiovascular Diseases (2)  ·  Disease Attributes (2)  ·  Hemorrhagic Disorders (2)  ·  Hemostatic Disorders (2)  ·  Immune System Diseases (2)  ·  Immunoproliferative Disorders (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Plasma Cell (2)  ·  Paraproteinemias (2)

Interventions

Bortezomib (1)  ·  Cyclophosphamide (1)  ·  Dexamethasone (1)  ·  Melphalan (1)  ·  Whole-Body Irradiation (1)  ·  fludarabine (1)  ·  fludarabine phosphate (1)  ·  isatuximab (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (1)  ·  Corewell Health West (1)  ·  Institut Paoli-Calmettes (1)  ·  Medical College of Wisconsin (1)  ·  Mirror Biologics, Inc. (1)  ·  Sanofi (1)

Countries

France (3)  ·  United States (3)  ·  Israel (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Chile (1)  ·  Finland (1)  ·  Greece (1)  ·  Italy (1)  ·  Mexico (1)  ·  Peru (1)  ·  Russia (1)  ·  Spain (1)  ·  Turkey (Türkiye) (1)

Top investigators

A. Samer Al-Homsi, MD (1)  ·  Dr. Michael Har-Noy (1)  ·  Mehdi Hamadani (1)

Results publications

PMID 32409691, PMID 33080623